This month marks 15 years since PLOS ONE published its first papers. As we celebrate this milestone, we invited authors of some of the first papers to be published, as well as an author of a more recent paper, to share information about their careers, their perspectives on Open Science, and their experiences as PLOS ONE authors.
E-Mail
IMAGE: The researchers analysed the contribution of the five main cell types involved in coronary artery disease. view more
Credit: UEF/Raija Törrönen
Using single cell technology, a new study sheds light on the significance of genetic risk factors for, and the diversity of cells involved in, the development of coronary artery disease. The researchers analysed human atherosclerotic lesions to map the chromatin accessibility of more than 7,000 cells. The chromatin accessibility is known to reflect active regions and genes in the genome. The findings were published in
Circulation Research.
Genome-wide association studies of the human genome have identified over 200 loci associated with coronary artery disease. More than 90% of them are located outside protein-coding genes, in so called cis-regulatory elements, whose significance in the pathogenesis of coronary artery disease remains unclear.
Finnish company receives funding to develop nasal spray Covid vaccine yle.fi - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yle.fi Daily Mail and Mail on Sunday newspapers.
Researchers at the University of Eastern Finland have uncovered potential mechanisms by which microRNAs (miRNA) drive atherogenesis in a cell-type-specific manner. Published in the Arteriosclerosis, Thrombosis, and Vascular Biology journal, the study provides novel insight into the miRNA profiles of the main cell types involved in atherosclerosis.
New technologies are expected to enhance nasal vaccines industry growth as particular attention is being paid to designing delivery strategies that take into account the broad range of diseases, populations and healthcare delivery settings that will benefit from the mucosal route of delivery. Key challenges for the nasal vaccines industry includes translating in vivo data to clinical outcomes